<DOC>
	<DOC>NCT00888745</DOC>
	<brief_summary>This is a Phase I multicenter study that will be conducted in the United States and Europe.</brief_summary>
	<brief_title>A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>RA diagnosed according to the American College of Rheumatology (ACR) Female patients who are pregnant, plan to become pregnant during the study, or are breastfeeding Clinically significant abnormal ECG History of anaphylactic reactions Positive hepatitis C antibody or hepatitis B surface antigen Positive serology for human immunodeficiency virus (HIV) by quantitative polymerase chain reaction A history of an autoimmune disease other than RA (other than secondary Sjogren syndrome) Significant systemic involvement of RA, including vasculitis, pulmonary fibrosis, or Felty syndrome Malignancy, or prior malignancy, other than nonmelanoma skin cancer, or cervical carcinoma in situ that has been resected Recent administration of a live, attenuated vaccine, or anticipation that such a live attenuated vaccine will be required during the study or within 60 days after the last dose Concomitant therapy with a biologic agent Recent exposure to any investigational agent Any current or recent signs or symptoms of infection requiring parenteral antibiotic administration Hospitalization for a clinically relevant event within the 4 weeks prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>RA</keyword>
</DOC>